Company Overview and News

 
Seoul shares fall on hawkish Fed, BOK rate freeze

6h english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- South Korean stocks lost ground Thursday as rising odds of interest rate hikes in the United States weighed on investor sentiment, while the Bank of Korea froze the key interest rate. The local currency fell against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
(LEAD) Seoul shares fall on hawkish Fed, BOK rate freeze

6h english.yonhapnews.co.kr
SEOUL, Oct. 18 (Yonhap) -- South Korean stocks lost ground Thursday as rising odds of interest rate hikes in the United States weighed on investor sentiment, while the Bank of Korea froze the key interest rate. The local currency fell against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
Hyundai, Kia reviewing US request to testify on engine fires

6h koreaherald
Hyundai Motor Co. and Kia Motors Corp., South Korea's two biggest carmakers by sales, said Thursday they are reviewing a US request to testify in regards to engine fires in their cars next month. Hyundai and Kia's US operations received the request from the Senate Commerce Committee to appear at a hearing on Nov. 14 on reports of engine fires in their vehicles. Management is "currently reviewing" the request, a Hyundai spokesman said over the phone.
HYUO KIMTF HYUP KIMTY HYUD

 
US Senate panel wants to question Hyundai, Kia over engine fire reports

6h channelnewsasia
The Republican chairman and the ranking Democrat on the Senate Commerce Committee said on Wednesday they have asked top U.S. executives at Hyundai Motor Co and Kia Motors Corp to testify at a Nov. 14 hearing on reports of engine fires involving vehicles from the Korean automakers.
HYUO KIMTF HYUP KIMTY HYUD

 
Thousands of Seoul taxi-drivers rally against plans for carpool service

6h channelnewsasia
SEOUL: Tens of thousands of South Korean taxi-drivers held a rally on Thursday (Oct 18) in Seoul, the capital, saying a carpooling service planned by the operator of the country's top chat app would threaten their livelihoods and jobs.
HYUO HYUP HYUD

 
Senate panel wants to question Hyundai, Kia over engine fire reports

2018-10-17 reuters
WASHINGTON (Reuters) - The Senate Commerce Committee’s Republican chairman and ranking Democrat said on Wednesday they had asked top U.S. executives at Hyundai Motor Co (005380.KS) and Kia Motors Corp (000270.KS) to testify at a Nov. 14 hearing on reports of engine fires involving vehicles from the Korean automakers.
HYUO KIMTF HYUP KIMTY HYUD

 
U.S. Senate panel wants Hyundai, Kia to testify on engine fire reports

2018-10-17 reuters
WASHINGTON (Reuters) - The Republican chairman and the ranking Democrat on the Senate Commerce Committee said on Wednesday they have asked top U.S. executives at Hyundai Motor Co (005380.KS) and Kia Motors Corp (000270.KS) to testify at a Nov. 14 hearing on reports of engine fires involving vehicles from the Korean automakers.
HYUO KIMTF HYUP KIMTY HYUD

 
US Senate panel wants Hyundai, Kia to testify on engine fire reports

2018-10-17 channelnewsasia
The Republican chairman and the ranking Democrat on the Senate Commerce Committee said on Wednesday they have asked top U.S. executives at Hyundai Motor Co and Kia Motors Corp to testify at a Nov. 14 hearing on reports of engine fires involving vehicles from the Korean automakers.
HYUO KIMTF HYUP KIMTY HYUD

 
Seoul shares rise on upbeat U.S. earnings

2018-10-17 english.yonhapnews.co.kr
SEOUL, Oct. 17 (Yonhap) -- South Korean stocks advanced Wednesday as strong earnings data and economic indicators from the United States boosted investor sentiment. The local currency strengthened against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
(LEAD) Seoul shares rise on upbeat U.S. earnings

2018-10-17 english.yonhapnews.co.kr
SEOUL, Oct. 17 (Yonhap) -- South Korean stocks advanced Wednesday as strong earnings data and economic indicators from the United States boosted investor sentiment. The local currency strengthened against the U.S. dollar.
HYUO BC94 SMSN HYUP HYUD SMSD

 
(LEAD) Seoul shares end flat amid global trade tensions

2018-10-16 english.yonhapnews.co.kr
SEOUL, Oct. 16 (Yonhap) -- South Korean stocks ended volatile trading unchanged from the previous session Tuesday amid lingering global trade tension and geopolitical risks in the Middle East. The local currency firmed against the U.S. dollar.
HYUO KIMTF BC94 SMSN HYUP KIMTY HYUD SMSD

 
Seoul shares end flat amid global trade tensions

2018-10-16 english.yonhapnews.co.kr
SEOUL, Oct. 16 (Yonhap) -- South Korean stocks ended volatile trading unchanged from the previous session Tuesday amid lingering global trade tension and geopolitical risks in the Middle East. The local currency firmed against the U.S. dollar.
HYUO KIMTF BC94 SMSN HYUP KIMTY HYUD SMSD

 
Hyundai Motor's leverage to improve over next 12-18 months: Moody's

2018-10-16 english.yonhapnews.co.kr
SEOUL, Oct. 16 (Yonhap) -- Moody's Investors Service, a global credit rating agency, on Tuesday said it expected Hyundai Motor Group's financial leverage to improve over the next 18 months on increasing profitability.
HYUO HYUP HYUD

 
Hyundai Motor's leverage to improve over next 12-18 months: Moody's

2018-10-16 koreaherald
Moody's Investors Service, a global credit rating agency, on Tuesday said it expected Hyundai Motor Group's financial leverage to improve over the next 18 months on increasing profitability.
HYUO HYUP HYUD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...